SG11201907725SA - Tri-cycle compound and applications thereof - Google Patents

Tri-cycle compound and applications thereof

Info

Publication number
SG11201907725SA
SG11201907725SA SG11201907725SA SG11201907725SA SG11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA
Authority
SG
Singapore
Prior art keywords
applications
tri
cycle compound
compound
cycle
Prior art date
Application number
SG11201907725SA
Other languages
English (en)
Inventor
Haiying He
Jing Wang
Zhigan Jiang
Yaxun Yang
Peng Shao
Chen Zhang
Jian Li
Shuhui Chen
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of SG11201907725SA publication Critical patent/SG11201907725SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201907725SA 2017-02-23 2018-02-09 Tri-cycle compound and applications thereof SG11201907725SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710100309 2017-02-23
CN201710648155 2017-08-01
CN201810008592 2018-01-04
PCT/CN2018/075995 WO2018153285A1 (fr) 2017-02-23 2018-02-09 Composé à trois cycles et ses applications

Publications (1)

Publication Number Publication Date
SG11201907725SA true SG11201907725SA (en) 2019-09-27

Family

ID=63253508

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907725SA SG11201907725SA (en) 2017-02-23 2018-02-09 Tri-cycle compound and applications thereof

Country Status (23)

Country Link
US (1) US11053260B2 (fr)
EP (1) EP3587420B1 (fr)
JP (1) JP6764039B2 (fr)
KR (1) KR102085497B1 (fr)
CN (1) CN109071544B (fr)
AU (1) AU2018223435B2 (fr)
BR (1) BR112019017603A2 (fr)
CA (1) CA3054324C (fr)
DK (1) DK3587420T3 (fr)
ES (1) ES2874656T3 (fr)
HU (1) HUE054822T2 (fr)
IL (1) IL268827A (fr)
LT (1) LT3587420T (fr)
MX (1) MX2019010042A (fr)
MY (1) MY175445A (fr)
PH (1) PH12019501955A1 (fr)
PL (1) PL3587420T3 (fr)
PT (1) PT3587420T (fr)
RS (1) RS61913B1 (fr)
SG (1) SG11201907725SA (fr)
SI (1) SI3587420T1 (fr)
WO (1) WO2018153285A1 (fr)
ZA (1) ZA201906135B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210052603A1 (en) * 2018-05-03 2021-02-25 Emory University Modulators of orphan nuclear receptors for nash and other metabolic disorders
EP3854797B1 (fr) * 2018-08-23 2023-03-15 Fujian Akeylink Biotechnology Co., Ltd. Forme cristalline d'un composé à trois cycles et utilisation associée
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
WO2021027566A1 (fr) * 2019-08-15 2021-02-18 福建广生堂药业股份有限公司 Procédé de préparation d'un composé d'oxazépine
CN115702152A (zh) * 2020-04-22 2023-02-14 南京明德新药研发有限公司 内磺酰胺衍生物及其应用
CN115515596A (zh) * 2020-05-15 2022-12-23 福建广生中霖生物科技有限公司 包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
CN114456099A (zh) * 2022-02-21 2022-05-10 八叶草健康产业研究院(厦门)有限公司 一种4-氯吡咯-2-羧酸的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
CN102060786A (zh) 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
EP3068774B1 (fr) 2013-11-14 2019-12-25 Novira Therapeutics Inc. Dérivés d'azépane et procédés de traitement d'infections par le virus de l'hépatite b
ES2748029T3 (es) 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
EP3143020B1 (fr) * 2014-05-13 2019-08-21 F. Hoffmann-La Roche AG Dihydroquinolizinones pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CN108431004B (zh) * 2015-10-23 2021-02-12 武田药品工业株式会社 杂环化合物
WO2018053157A1 (fr) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Modulateurs des protéines du noyau de l'hépatite b

Also Published As

Publication number Publication date
US11053260B2 (en) 2021-07-06
PL3587420T3 (pl) 2021-10-11
IL268827A (en) 2019-11-03
US20200247819A1 (en) 2020-08-06
CN109071544A (zh) 2018-12-21
ES2874656T3 (es) 2021-11-05
BR112019017603A2 (pt) 2020-03-24
CN109071544B (zh) 2020-03-17
DK3587420T3 (da) 2021-06-07
PH12019501955A1 (en) 2020-07-06
LT3587420T (lt) 2021-07-12
EP3587420A1 (fr) 2020-01-01
KR102085497B1 (ko) 2020-03-05
MY175445A (en) 2020-06-29
KR20190120300A (ko) 2019-10-23
PT3587420T (pt) 2021-06-04
RS61913B1 (sr) 2021-06-30
EP3587420A4 (fr) 2020-02-19
ZA201906135B (en) 2021-04-28
AU2018223435B2 (en) 2020-12-24
AU2018223435A1 (en) 2019-10-10
JP2020508342A (ja) 2020-03-19
SI3587420T1 (sl) 2021-09-30
EP3587420B1 (fr) 2021-03-31
JP6764039B2 (ja) 2020-09-30
CA3054324A1 (fr) 2018-08-30
MX2019010042A (es) 2020-01-13
HUE054822T2 (hu) 2021-10-28
WO2018153285A1 (fr) 2018-08-30
CA3054324C (fr) 2020-12-01

Similar Documents

Publication Publication Date Title
PH12018550120A1 (en) Steroid derivative fxr agonist
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
ZA202202097B (en) Amino pyrimidine ssao inhibitors
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12019500480A1 (en) Pyridine compound
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MY194116A (en) Pharmaceutical compounds
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
PH12016502246B1 (en) Carboxamide derivatives
TN2016000491A1 (en) Carboxamide derivatives.
MX2019010108A (es) Derivados de azetidina.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EA201991910A1 (ru) Трициклическое соединение и пути его применения
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
PH12016502247A1 (en) Carboxamide derivatives